The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.
As prescription drug prices in the US continue to rise, political leaders across administrations, including recently US ...
Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback